Invention Grant
- Patent Title: Dosage regimes for the administration of an anti-CD19 ADC
-
Application No.: US16622649Application Date: 2018-06-14
-
Publication No.: US11318211B2Publication Date: 2022-05-03
- Inventor: Jay Marshall Feingold , David Rodney Ungar
- Applicant: ADC THERAPEUTICS SA , MEDIMMUNE LIMITED
- Applicant Address: CH Epalinges; GB Cambridge
- Assignee: ADC THERAPEUTICS SA,MEDIMMUNE LIMITED
- Current Assignee: ADC THERAPEUTICS SA,MEDIMMUNE LIMITED
- Current Assignee Address: CH Epalinges; GB Cambridge
- Agency: Casimir Jones, S.C.
- Agent Lisa L. Mueller
- Priority: GB1709440 20170614,GB1709444 20170614,GB1710494 20170630,GB1710495 20170630,GB1720542 20171208,GB1720543 20171208,GB1802679 20180220,GB1808473 20180523
- International Application: PCT/EP2018/065873 WO 20180614
- International Announcement: WO2018/229222 WO 20181220
- Main IPC: A61K47/68
- IPC: A61K47/68 ; A61P35/02 ; A61K31/5517 ; C07K16/28 ; A61K31/519 ; A61K31/573 ; A61K31/7068 ; A61K39/00 ; A61K9/00
Abstract:
The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCS).
Public/Granted literature
- US20200171164A1 DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC Public/Granted day:2020-06-04
Information query
IPC分类:
